Skip to main content

Advertisement

SpringerLink
Log in

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

From April 2016, carfilzomib, in combination with lenalidomide and dexamethasone (KRD), became available for use in the daily practice in Italy for patients with relapsed or refractory multiple myeloma (RRMM). We performed a retrospective survey at 14 different institutions from Southern Italy in order to evaluate patient characteristics and treatment results from an unselected series of patients treated accordingly so far. One hundred and twenty-three consecutive patients were included, with a median of 2 previous lines of therapy (range 1–9) and a median age of 63 years (range 39–82). At the time of analysis, median number of courses administered is 11 (range 1–34), and all patients are evaluable for response. Overall response rate including complete remission, very good partial remission, and partial remission is 85%. After a median follow-up of 27 months, median overall and progression-free survival are 33 and 23 months, respectively. Sixty-three patients are alive and between them, 45 (37%) are in continuous remission. Sixty patients have died (49%), mainly from progressive disease. There were 6 treatment-related deaths (5% of the whole patient population). Overall, hematological and non-hematological toxicity were manageable, mostly on outpatient basis. Arterial hypertension has been observed in 43 cases (35%) but did not lead to treatment interruption. Our data demonstrate that in real life, KRD is highly effective and well tolerated in the majority of patients with RRMM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, Terebelo HR, Toomey K, Wagner L, Srinivasan S, Kitali A, Yue L, Flick ED, Agarwal A, Rifkin RM (2018) Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016). Clin Lymphoma Myeloma Leuk 18(7):480–485

    Article  Google Scholar 

  2. Anderson KC (2016) Progress and paradigms in multiple myeloma. Clin Cancer Res 22(22):5419–5427

    Article  CAS  Google Scholar 

  3. Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ (2017) Practical considerations in managing relapsed multiple myeloma. Clin Lymphoma Myeloma Leuk 17(2):69–77

    Article  Google Scholar 

  4. Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, de Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M, Bekadja M, Hamladji RM, Ali HA, Hamdi S, Touhami H, Mansour NS, Willenbacher W, Linkesch W, Nemet D, Pedersen RS, Abildgaard N, Laane E, Hein M, Mohty M, Eveillard JR, Yamani A, Moreau P, Sanhes L, Lepeu G, Laribi K, Jourdan E, Fitoussi O, Allangba O, Fleury J, Escoffre M, Benramdane R, Cartron G, Dine G, Legouffe E, Harich HD, Illmer T, Dörfel S, Hannig CV, Koenigsmann M, Prange-Krex G, Salwender H, Tamm I, Zeller W, Maasberg M, Schlag R, Klausmann M, Uhlig J, Alkemper B, Schütz S, Tessen HW, Mohr B, Schmidt P, Heinrich B, Hebart H, Seipelt G, Zoeller T, Heits F, Müller-Naendrup C, Hansen R, Repp R, von Weikersthal LF, Schmits R, Heßling J, Krammer-Steiner B, Janzen V, Schauer M, Grüner MW, Kisro J, Denzlinger C, Freier W, Junghanss C, Görner M, Laichinger K, Ostermann H, Dürk H, Hess G, Reich G, Terpos E, Dimopoulos M, Matsouka P, Pouli A, Anagnostopoulos A, Masszi T, Borbényi Z, Ivanyi J, Szomor A, Abadi U, Nagler A, Magen H, Avivi I, Quitt M, Palumbo A, Boccadoro M, de Stefano V, Za T, Vallisa D, Foa R, Corso A, Bosi A, Vacca A, Lanza F, Palazzo G, Avvisati G, Cavo M, Ferrara F, Consoli U, Cantonetti M, Angelucci E, Califano C, di Raimondo F, Guarini A, Musso M, Pizzuti M, Giuliani N, Ardizzoia A, di Renzo N, Gaidano G, Gozzetti A, Pitini V, Farina G, Centurioni R, de Fabritiis P, Iuliano F, la Nasa G, la Verde G, Pane F, Recine U, la Targia M, Mineo G, Cangialosi C, Fagnani D, Federici A, Romano A, Specchia G, Storti S, Bongarzoni V, Bacigalupo A, Gobbi M, Latte G, Mannina D, Capalbo S, Lejniece S, Pečeliūnas V, Jurgutis M, Stankovic S, Legiec W, Woszczyk D, Hołojda J, Gornik S, Pluta A, Morawiec-Szymonik E, Kyrcz-Krzemien S, Homenda W, Grosicki S, Sulek K, Lange A, Kloczko J, Starzak-Gwozdz J, Hellmann A, Komarnicki M, Kuliczkowski K, Viveiros C, Gonçalves C, Esefyeva N, Kochkareva J, Kaplanov K, Volodicheva E, Laricheva E, Dergacheva V, Chukavina M, Volchenko N, Nazarova I, Anchukova L, Ovanesova E, Gritsenko T, Salogub G, Magomedova L, Kuznetsova I, Osyunikhina S, Serdyuk O, Karyagina E, Ivanova V, Černelč SP, Louw V, Coetzee C, Gunther K, Moodley D, Duran S, Gutiérrez AE, de Oteyza JP, Capote FJ, Casanova M, Sanchez JM, Rios-Herranz E, Ibañez-Garcia J, Herranz MJ, Hernandez B, Sanchez SS, Escalante F, Carnicero F, Lleonart JB, Gironella M, Martínez R, de la Guia AL, Palomera L, Iglesias R, Ramos FS, de la Serna J, Sanchez PG, Vidal JB, Mateos MV, Morfa MD, Beksac T–M, Vural F, Aydin Y, Unal A, Goker H, Bilgir O, Guvenc B, Turgut M, Ozet GG, Ali R, Masliak Z, Kyselyova M, Glushko N, Vybyrana R, Skrypnyk I, Tretyak N, Kharchevska T, Dyagil I, Popovs'ka T, Shimanskiy V, Lysa T, Oliynyk H, Vilchevskaya K, Kryachok I, Popovych Y, Romanyuk N, Yushchenko N, Kaplan P, Rekhtman G, Pylypenko H, Kozlov V, Mohty M, Terpos E, Mateos MV, Palumbo A, Drach J, Boccadoro M, Harousseau JL, Einsele H, Goldschmidt H, Facon T, Michalet M, Savchenko VG, de la Rubia J, Cook G, Mellqvist UH, Ludwig H (2018) Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk 18(10):e401–e419. https://doi.org/10.1016/j.clml.2018.06.018

    Article  PubMed  Google Scholar 

  5. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, ASPIRE Investigators (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152

    Article  Google Scholar 

  6. Niesvizky R, Martin TG III, Bensinger WI et al (2013) Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalido- mide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 19:2248–2256

    Article  CAS  Google Scholar 

  7. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R (2013) Phase 2 dose-expansion study (PX-171- 006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122:3122–3128

    Article  CAS  Google Scholar 

  8. Tzogani K, Camarero Jiménez J, Garcia I, Sancho-López A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F (2017) The European medicines agency review of carfilzomib for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Oncologist 22(11):1339–1346

    Article  CAS  Google Scholar 

  9. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, ENDEAVOR Investigators (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38

    Article  CAS  Google Scholar 

  10. Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H (2016) Efficacy and safety of salvage therapy using carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol 172(1):89–96

    Article  CAS  Google Scholar 

  11. Rifkin RM, Medhekar E, Amirian SE et al (2019) A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. Ther Adv Hematol 10:1–10

    Article  Google Scholar 

  12. Antonioli E, Staderini M, Nozzoli C et al (2017) “Real-life” experience of carfilzomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients. Haematologica 102(s3):131–132

    Google Scholar 

  13. Barilà G, Meneghini V, Bonalumi A et al (2018) KRD treatment of relapsed/refractory multiple myeloma patients: a real life experience. Hemasphere 2(s1):978–979

    Google Scholar 

  14. Calafiore V, Martino E, Parisi M et al (2018) Efficacy, safety and tolerability of carfilzomib- lenalidomide-dexamethasone (KRD) regimen in RR/MM. Haematologica 103(s1):35–36

    Google Scholar 

  15. Guidotti F, Ferla V, Gregorini AI, Rossi FG, Pompa A (2018) Carfilzomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma: a single centre real-life experience. Haematologica 103(s1):38

    Google Scholar 

  16. Terpos E, Caers J, Sohne M et al (2018) Real-world evidence of the use of carfilzomib among patients with relapsed multiple myeloma in Europe: an interim analysis for a prospective observational study. Hemasphere 2(s1):962

    Google Scholar 

  17. Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E (2017) Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv 1(7):449–454

    Article  CAS  Google Scholar 

  18. Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N (2018) Outcome of salvage third autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 24(7):1372–1378

    Article  Google Scholar 

  19. Hagen PA, Stiff P (2018) The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma. Biol Blood Marrow Transplant 25:e98–e107. https://doi.org/10.1016/j.bbmt.2018.12.002

    Article  CAS  PubMed  Google Scholar 

  20. Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P (2018) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol 11(1):49. https://doi.org/10.1186/s13045-018-0583-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK (2018) Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 19(7):953–964

    Article  CAS  Google Scholar 

  22. Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, de Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M (2018) Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia 32(8):1803–1807

    Article  CAS  Google Scholar 

  23. Dimopoulos MA, Oriol A, Nahi H, POLLUX Investigators et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology, “Cardarelli” Hospital, Naples, Italy

    Salvatore Palmieri, S. Rocco, O. Vitagliano & F. Ferrara

  2. Hematology, AUOP “Federico II”, Naples, Italy

    L. Catalano, C. Cerchione & F. Pane

  3. Hematology Unit, “Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy

    I. D. Vincelli & A. Scopelliti

  4. Onco-Hematology, Hematology Unit, AO of Cosenza, Italy

    M. Gentile

  5. Onco-Hematology, “S. Anna e S. Sebastiano” Hospital, Caserta, Italy

    G. Farina

  6. Onco-Hematology, “Tortora” Hospital, Pagani, SA, Italy

    M. Barone

  7. Hematology, “Santa Maria di Loreto Nuovo” Hospital, Naples, Italy

    A. Gagliardi

  8. Hematology, “San Giuseppe Moscati” Hospital, Aversa, CE, Italy

    D. Esposito

  9. Hematology/Oncology and SCT Unit, National Cancer Institute, Fondazione “Pascale”, Naples, Italy

    M. Arcamone

  10. Hematology, “Rummo” Hospital, Benevento, Italy

    V. Amico

  11. Hematology, AOU “Ruggi d’Aragona”, Salerno, Italy

    R. Fontana

  12. Hematology and SCT Unit, “San Giuseppe Moscati” Hospital, Avellino, Italy

    A. Sementa

  13. Onco-Hematology, AOU “Vanvitelli”, Naples, Italy

    A. Sica

  14. Hematology, “San Giuliano” Hospital, Giugliano in Campania, Naples, Italy

    G. Svanera

Authors
  1. Salvatore Palmieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Rocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Vitagliano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Cerchione
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. D. Vincelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Scopelliti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Gentile
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Farina
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Gagliardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D. Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Arcamone
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. V. Amico
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. R. Fontana
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Sementa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A. Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. G. Svanera
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. F. Pane
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. F. Ferrara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salvatore Palmieri.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Palmieri, S., Rocco, S., Vitagliano, O. et al. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol 99, 2903–2909 (2020). https://doi.org/10.1007/s00277-020-04158-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04158-4

Keywords

Search

Navigation